Abstract

Background: In Iran, ovarian cancer is the eighth most common cancer. Serous is considered as the most common of all ovarian cancers. It is usually deadly due to late diagnosis. Moreover, as all studies so far, have considered metastatic or high stage ovarian cancer, this study sought low grade ovarian serous in human which is of high importance and aimed at obtaining protein biomarkers that may be useful in diagnosis and treatment of ovarian serous cancer. Materials and Methods: In this experimental study, 10 patients with proved low grade serous ovarian cancer and 10 women without ovarian cancer, healthy and cancerous tissue samples were obtained to perform proteomics. All tissue proteins were purified using standard separation methods and proteins were separated using two-dimensional electrophoresis. Healthy and tumorous tissue proteomes were compared and the extent of protein expression was analyzed. Results: This study identified 212 proteins, 41 of which had changes in protein expression in cancer state. The expression of 8 proteins was suppressed and 5 proteins were expressed in cancerous group. Thirteen proteins in cancer sample showed increase in expression and 15 proteins reduced expression in cancerous tissue. Conclusion: It seems that in this disease, the expression of a large number of proteins in cancerous tissues changed, most of them decreased or not expressed at all. These changed proteins can be effective as biomarker in diagnosis and treatment of this disease.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.